LiRong Wang

Dr. LiRong Wang


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2016 in Scientific Reports
Verified
Journal Article
Open access
HZHai Zhang
Hai Zhang
SMShifan Ma
Shifan Ma
ZFZHIWEI FENG
ZHIWEI FENG
DWDongyao Wang
Dongyao Wang
CLChengjian Li
Chengjian Li
XXXiang-Qun Xie
Xiang-Qun Xie
Combination therapy is a popular treatment for various diseases in the clinic. Among the successful cases, Traditional Chinese Medicinal (TCM) formulae can achieve synergistic effects in therapeutics and antagonistic effects in toxicity. However, characterizing the underlying molecular synergisms for the combination of drugs remains a challenging task due to high experimental expenses and complication of multicomponent herbal medicines. To understand the rationale of combination therapy, we investigated Sini Decoction, a well-known TCM consisting of three herbs, as a model. We applied our established diseases-specific chemogenomics databases and our systems pharmacology approach TargetHunter to explore synergistic mechanisms of Sini Decoction in the treatment of cardiovascular diseases. (1) We constructed a cardiovascular diseases-specific chemogenomics database, including drugs, target proteins, chemicals, and associated pathways. (2) Using our implemented chemoinformatics tools, we mapped out the interaction networks between active ingredients of Sini Decoction and their targets. (3) We also in silico predicted and experimentally confirmed that the side effects can be alleviated by the combination of the components. Overall, our results demonstrated that our cardiovascular disease-specific database was successfully applied for systems pharmacology analysis of a complicated herbal formula in predicting molecular synergetic mechanisms, and led to better understanding of a combinational therapy.

1 January 2014 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
XXXiang-Qun Xie
Xiang-Qun Xie
LiRong WangLiRong Wang
LiRong Wang
HLHaibin Liu
Haibin Liu
QOQin Ouyang
Qin Ouyang
CFCheng Fang
Cheng Fang
WSWeiwei Su
Weiwei Su
Drug abuse (DA) and addiction is a complex illness, broadly viewed as a neurobiological impairment with genetic and environmental factors that influence its development and manifestation. Abused substances can disrupt the activity of neurons by interacting with many proteins, particularly G-protein coupled receptors (GPCRs). A few medicines that target the central nervous system (CNS) can also modulate DA related proteins, such as GPCRs, which can act in conjunction with the controlled psychoactive substance(s) and increase side effects. To fully explore the molecular interaction networks that underlie DA and to effectively modulate the GPCRs in these networks with small molecules for DA treatment, we built a drug-abuse domain specific chemogenomics knowledgebase (DA-KB) to centralize the reported chemogenomics research information related to DA and CNS disorders in an effort to benefit researchers across a broad range of disciplines. We then focus on the analysis of GPCRs as many of them are closely related with drug abuse. Their distribution in human tissues was also analyzed for the study of side effects caused by abused drugs. We further implement our computational algorithms/tools to explore DA targets, DA mechanisms and pathways involved in polydrug addiction and to explore polypharmacological effects of the GPCR ligands. Finally, the polypharmacology effects of GPCR-targeted medicines for drug abuse treatment were investigated and such effects can be exploited for the development of drugs with polypharmacophore for drug abuse intervention. The chemogenomics database and the analysis tools will help us better understand the mechanism of drugs abuse and facilitate to design new medications for system pharmacotherapy of drug abuse.

29 October 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MGMichael Gilbert
Michael Gilbert
ALAndrew La
Andrew La
NDNoah Delapaz
Noah Delapaz
WHWilliam Hor
William Hor
PFPeihao Fan
Peihao Fan
LiRong WangLiRong Wang
LiRong Wang
Benzodiazepines is a class of medications frequently prescribed to patients with post-traumatic stress disorder. Patients with PTSD have a notable increased risk of suicide compared to the general population. These medications have been theorized to increase suicidality and pose a risk when used in this patient population. Previous research has found little utility of using benzodiazepines in the PTSD population. However, benzodiazepines are still commonly prescribed by some clinicians for their symptomatic benefit. This study aims to identify the comparative efficacy of commonly prescribed benzodiazepines including midazolam, lorazepam, alprazolam, clonazepam, diazepam and temazepam in relation to suicide-related behaviors (SRBs). A total of 38,807 patients who had an ICD9 or ICD10 diagnosis of PTSD from January 2004 to October 2019 were identified through an electronic medical record database. Inclusion criteria include patients that initiated one of the above benzodiazepines after PTSD diagnosis. Exclusion criteria include previous history of benzodiazepine usage or history of SRBs within the last year prior to enrollment. For patients enrolled in this study, other concomitant drugs were not limited. The primary outcome was onset of SRBs with each respective benzodiazepine. SRBs were identified as ideation, attempt, or death from suicide. We emulated clinical trials of head-to-head comparison between two drugs by pooled logistic regression methods with the Firth option adjusting for baseline characteristics and post-baseline confounders. A total of 5753 patients were eligible for this study, with an average follow up of 5.82 months. The overall incidence for SRB was 1.51% (87/5753). Head-to-head comparisons identified that patients who received alprazolam had fewer SRBs compared to clonazepam (p = 0.0351) and lorazepam (p = 0.0373), and patients taking midazolam experienced fewer relative incidences of SRBs when compared to lorazepam (p = 0.0021) and clonazepam (p = 0.0297). After adjusting for the false discovery rate (FDR), midazolam still had fewer SRBs compared to lorazepam (FDR-adjusted p value = 0.0315). Certain benzodiazepines may provide a reduced risk of development of SRBs, suggesting careful consideration when prescribing benzodiazepines to the PTSD population.

21 June 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PFPeihao Fan
Peihao Fan
OMOshin Miranda
Oshin Miranda
XQXIGUANG QI
XIGUANG QI
JKJulia Kofler
Julia Kofler
RSRobert Sweet
Robert Sweet
LiRong WangLiRong Wang
LiRong Wang
Around 50% of patients with Alzheimer’s disease (AD) may experience psychotic symptoms after onset, resulting in a subtype of AD known as psychosis in AD (AD + P). This subtype is characterized by more rapid cognitive decline compared to AD patients without psychosis. Therefore, there is a great need to identify risk factors for the development of AD + P and explore potential treatment options. In this study, we enhanced our deep learning model, DeepBiomarker, to predict the onset of psychosis in AD utilizing data from electronic medical records (EMRs). The model demonstrated superior predictive capacity with an AUC (area under curve) of 0.907, significantly surpassing conventional risk prediction models. Utilizing a perturbation-based method, we identified key features from multiple medications, comorbidities, and abnormal laboratory tests, which notably influenced the prediction outcomes. Our findings demonstrated substantial agreement with existing studies, underscoring the vital role of metabolic syndrome, inflammation, and liver function pathways in AD + P. Importantly, the DeepBiomarker model not only offers a precise prediction of AD + P onset but also provides mechanistic understanding, potentially informing the development of innovative treatments. With additional validation, this approach could significantly contribute to early detection and prevention strategies for AD + P, thereby improving patient outcomes and quality of life.

18 March 2011 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
PDF file
LiRong WangLiRong Wang
LiRong Wang
ZXZhaojun Xie
Zhaojun Xie
PWPeter Wipf
Peter Wipf
XXXiang-Qun Xie
Xiang-Qun Xie

1 November 2016 in Journal of Molecular Graphics and Modelling
Verified
Journal Article
Closed access
XXXiaomeng Xu
Xiaomeng Xu
SMShifan Ma
Shifan Ma
ZFZHIWEI FENG
ZHIWEI FENG
GHGuanxing Hu
Guanxing Hu
LiRong WangLiRong Wang
LiRong Wang
XXXiang-Qun Xie
Xiang-Qun Xie